The field of Urologic Oncology has witnessed tremendous changes. The horizon of scientific knowledge has widened with preventive efforts leading to the earliest detection of cancer and insight into the mechanisms of cancer leading to rational changes into the medical armamentarium. While urological cancer was diagnosed and treated mostly by urologists only this has been replaced by multidisciplinary teams with equal roles for all members. Oncologic Urology with emphasis on Urology has been replaced by Urologic Oncology with emphasis on Oncology. This fundamental change has revolutionized daily practice for uro-oncology patients. Centralization of care is ongoing at a tremendous speed enabling all patients to benefit from standard of care treatment. Surgery as the mainstay of cancer treatment is gradually moving backwards. Organ sparing therapy and image guided therapy are replacing the traditional ablative surgery. On the other hand surgery is considered essential in patients in whom it was thought to be irrelevant. Primary tumor surgery in metastatic patients is a new outlook on advanced cancer treatment.

With immunotherapy swiftly marching to the forefront of cancer treatment, surgery will be used as another treatment modality removing metastases at a previously unheard scale.

A testimony of these changes is to be found in the 1st edition of Urinary System Tumor, a compilation of multidisciplinary endeavours in the field of urologic oncology.

Simon Horenblas, MD, PhD, FEBU
Chief Department Urology
Netherlands Cancer Institute, Amsterdam, The Netherlands
Email: s.horenblas@nki.nl